Drug Trial Radar · NCT00700856
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial
Last checked: Nov 19, 2026Latest source record: Aug 27, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,371
Planned (sponsor's estimate)
Start
Sep 2008
Primary completion
Dec 2018
Study completion Dec 2018
Sponsor
- Lead sponsor
- Italian Society of DiabetologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Associazione Medici Diabetologi (AMD); Associazione Nazionale Medici Cardiologi Ospedalieri
- First posted
- Jun 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background: In patients with type 2 diabetes inadequately controlled with metformin, two main therapeutic options are equally plausible: add-on a sulfonylurea (SU) or a thiazolidinedione (TZD). Since the two classes of drugs clearly differ in terms of mechanisms of action, side effects, economic costs and cardiovascular risk factors profile, a direct comparison of the two therapeutic strategies would be most appropriate. Aims: 1) To evaluate the effects of add-on pioglitazone as compared with add-on a SU on the incidence of cardiovascular events in type 2 diabetic patients inadequately controlled with metformin; 2) To compare the two treatments in terms of glycemic control, safety, and economic costs. Methods: multicentre, randomised, open label, parallel group trial of 48 months duration. Eligible participants (type 2 diabetic males and females, aged 50-75 years, BMI 20-45 Kg/m2, in treatment for the last two months with metformin 2 gr/die in monotherapy and with HbA1c \> =7.0% and \<= 9.0%) will be randomized to add-on: a SU - glibenclamide (5-15 mg/die), gliclazide (30-120 mg/die), glimepiride (2-6 mg/die), chosen according to local practice - or pioglitazone (15-45 mg/die). A HbA1c value \> 8.0 % on two consecutive occasions will lead to addition of insulin to ongoing oral therapy. Primary efficacy outcome: a composite endpoint of all-cause mortality, non fatal MI (including silent MI), non fatal stroke, and unplanned coronary revascularization. Secondary outcomes. Principal secondary outcome: a composite ischemic endpoint of sudden death, fatal and non fatal acute MI (including silent MI), fatal and non fatal stroke, major amputations (above ankle), endovascular or surgical intervention on the coronary, leg or carotid arteries. Other secondary outcomes \- a composite cardiovascular end point including the primary end point plus hospitalization for heart failure, endovascular or surgical intervention on the coronary, leg or carotid arteries, silent MI, angina - by WHO criteria and confirmed by a new electrocardiogram abnormality - intermittent claudication with an ankle/brachial index lower than 090; events of heart failure; a microvascular endpoint including: plasma creatinine increase of 2 times above the baseline value or creatinine clearance reduction of 20ml/min/1. 73m2 or development of overt nephropathy (dialysis or plasma creatinine \>3,3 mg/dl) or macroalbuminuria; glycemic control (changes from baseline in HBA1c, time to failure of glycemic control, i.e., HBA1c \>8.0% on two consecutive occasions three months apart); major CV risk factors (lipids, blood pressure, microalbuminuria, inflammation markers, waist circumference); safety and side effects; direct and indirect costs. Data regarding CV endpoints, safety, tolerability, and study conduct will be monitored and analyzed by an independent committee, and will be not available to the study investigators until the closing of data collection. Efficacy end points will be analyzed on an intention-to-treat basis.
Conditions
- Type 2 Diabetes Mellitus
- Cardiovascular Disease
Interventions
add-on pioglitazoneDrug
participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
add-on sulphonylureaDrug
participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
Primary outcomes
What the sponsor says the trial is designed to measure.
- A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularizationTime frame: 48 months
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Inrca - Irccs
Ancona, Italy
San Donato Hospital
Arezzo, Italy
University of Bari
Bari, Italy
Ospedali Riuniti di Bergamo
Bergamo, Italy
Policlinico S. Orsola Malpigli
Bologna, Italy
Presidio Ospedaliero A.S.RE.Molise
Campobasso, Italy
"Garibaldi di Nesima" Hospital
Catania, Italy
"Mater Domini" University
Catanzaro, Italy
M. Bufalini Hospital
Cesena, Italy
ASP
Cosenza, Italy
Arcispedale "S.Anna"
Ferrara, Italy
University of Ferrara
Ferrara, Italy
University of Florence
Florence, Italy
Ospedali Riuniti
Foggia, Italy
University of Genova
Genova, Italy
San Salvatore Hospital
L’Aquila, Italy
ASL Latina
Latina, Italy
Santa Maria Goretti Hospital
Latina, Italy
"Cittadella della Salute" Hospital
Lecce, Italy
ASL 6
Livorno, Italy
Hospital of Massa
Massa Carrara, Italy
Matera Hospital
Matera, Italy
"Ospedali Riuniti Papardo-Piemonte" Hospital
Messina, Italy
University of Messina
Messina, Italy
Istituto Scientifico San Raffaele
Milan, Italy
Niguarda Cà Grande Hospital
Milan, Italy
"Federico II" University
Naples, Italy
Second University
Naples, Italy
Complesso Sociosanitario dei Colli
Padua, Italy
University of Padua
Padua, Italy
University of Palermo
Palermo, Italy
University of Parma
Parma, Italy
University of Perugia
Perugia, Italy
Civil Hospital
Pescara, Italy
Ospedale Gugliemo da Saliceto
Piacenza, Italy
University of Pisa
Pisa, Italy
Spedali Riuniti di Pistoia
Pistoia, Italy
ASP
Potenza, Italy
Praia a Mare Hospital
Praia a Mare, Italy
Operative Unit of Diabetologia - ASL 4
Prato, Italy
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.